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Abstract
Background: The subgingival microbiota as well as determination of markers such as
associated pathogens is still in the focus of dental research. The aim of this controlled
clinical trial was to determine clinical applicability of a newly developed chairside
bacterial test (CST) for the most relevant periodontal pathogens.
Methods: Within 125 participants (100 with periodontitis, 25 healthy) two sulcus
fluid samples each were collected and pooled for further analysis. Samples were ana-
lyzed with CST and results (positive signals for every pathogen/control) were visually
detected by eye. As a reference quantitative polymerase chain reaction (qPCR) was
performed.
Results: The detection limit of CST revealed 1.2 × 104 for Treponema denticola
(T.d.) and Tannerella forsythia (T.f.), 2.5 × 104 for Porphyromonas gingivalis (P.g.),
5.3 × 103 for Prevotella intermedia (P.i.), and 5.8 × 104 for Aggregatibacter acti-
nomycetemcomitans (A.a.). Based on this maximum potential of positive detections,
the sensitivities of CST in reference to qPCR were: T.d. (91.3%); T.f. (86.3%); P.g.
(83.8%); P.i. (85.7%), and A.a. (100%). In regard to the clinical diagnosis, the CST
assay and the qPCR method reached a sensitivity of 87.82% and 94%, respectively.
The specificity for both methods was 100%.
Conclusion: This newly developed CST can detect five typical periodontal pathogens
with a somewhat lower sensitivity towards qPCR that can be classified as “good.”
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1 INTRODUCTION
Based on current scientific knowledge, various types of peri-
odontal pathogens are of significance in disease initiation
and progression, and therefore, for its treatment and prog-
nosis. While a plethora of bacteria (>700 bacterial species)
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original
work is properly cited.
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colonize the subgingival area, key species were identified
having a high evidence for a striking association with peri-
odontal disease (pocket depth and bleeding on probing [BOP])
such as Aggregatibacter actinomycetemcomitans (A.a.),
Porphyromonas gingivalis (P.g.), Tannerella forsythia (T.f.),
Treponema denticola (T.d.), and Prevotella intermedia
J Periodontol. 2019;00:1–9. wileyonlinelibrary.com/journal/jper 1
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(P.i.).1,2 These bacteria are also often associated with other
species, which results in a complex network of metabolic pro-
cesses leading to an increase in its pathogenicity.2,3
The usefulness of microbiological testing is the subject of
a very controversial debate among scientists. Critics point
out that it is not a requirement for proper treatment and
patients benefited from antibiotics irrespective of the knowl-
edge of the bacterial status.4–6 Especially the fact of being A.
actinomycetemcomitans-positive or -negative did not change
the effect of the antibiotics.4 Proponents invoke that tests are a
useful tool in finding the optimal and individualized treatment
option to patients, in particular, when used on patients with
(former classified) severe chronic or aggressive periodonti-
tis who do not respond favorably to conventional mechani-
cal therapy.7–9 Studies presenting trends in antibiotic use and
presenting some inappropriate prescriptions of second choice
antibiotics and emerging antibiotic resistance emphasize that
specific microbiological diagnostic tests can be supportive
for clinical practitioners.10 Furthermore, a recent study pre-
sented clinical findings that (appear to) support the use of
microbiological testing to strengthen the clinical decision
for either using or not using systemic antibiotics in con-
junction with non-surgical periodontal therapy.11 Consider-
ing World Health Organization (WHO) and European Union
(EU) statements12 (summarized in ref. 13) that resistance to
common bacteria has reached alarming levels and also den-
tists have to reconsider their antibiotic use and adopt proactive
and rational strategies (such as 1) avoidance of unnecessary
use of any antibiotic, 2) use of narrow-spectrum antibiotics
whenever possible, and 3) avoidance of broad-spectrum or
combination antibiotics besides in cases of severe infections
that do not respond otherwise); microbiological diagnosis is
advised before selecting antibiotics against infectious diseases
in general and periodontal diseases in particular.3,12–14
A recent systematic review6 contrasts all the pros and
cons and even considers a personalized approach to therapy
which includes a targeted microbial approach for the elim-
ination of periodontopathogenic bacteria based on baseline
microbial profiles as proposed already decades ago.15 They
even state that the new post-aggressive periodontitis/chronic
periodontitis16 baseline subgingival microbial profiling could
become a useful tool for decision on adjunctive antibiotic
use.
Finally, they found no support for this approach on their
meta-analysis data and conclude that they can not support
nor completely disregard baseline detection of periodon-
topathogenic bacteria.
While it was shown in previous studies that microbiologi-
cal testing itself could lead to more antibiotic prescription,17
all authors are in agreement that clinicians should not
empirically and not indiscriminately select antibiotic treat-
ment regimens, especially for patients with mild-to-moderate
periodontitis.4,10,11,18
While antibiotics were initially proposed to treat periodon-
titis caused by bacteria that have the ability to attach strongly
to and penetrate periodontal tissues or dentin tubules and
are difficult to be removed mechanically (such as A.a. and
P.g.),3,19 antibiotic regimens were later extended to periodon-
titis with other microbiological profiles since they could also
benefit especially in pockets ≥6 mm.4,20
For the clinical practitioner not very experienced with
the different forms of periodontitis, microbiological testing
can be a helpful tool for quality assurance and can help
choose a personalized treatment approach. In this context it is
important that positive results of microbiological testing do
not necessarily imply antibiotic prescription, since most of
subgingival bacteria can successfully be reduced by mechan-
ical treatment only.21
Many microorganisms largely present in periodontal pock-
ets are not cultivable,22,23 and standard microbiological culti-
vating procedures are unsuccessful. Other immunological and
molecular procedures such as quantitative polymerase chain
reaction (qPCR) for determination of bacterial DNA have
gained more and more importance. These procedures are of
higher sensitivity and specificity and require no live bacterial
cultures. Collected samples are sent to an external laboratory
and require 4 to 7 days for processing. Therefore, a disadvan-
tage of these methods is that appropriate treatment planning
and measures (e.g., targeted antibiotic treatment) occur with
delay. A faster processing and immediate assessment of the
sample directly at the patient (chairside) would save time.
Such so called point-of-care (POC) tests are already estab-
lished in general medicine for blood coagulation, cardiovas-
cular, and immunological markers, as well as for the analy-
sis of urine. Especially pregnancy, blood glucose and recently
also HIV tests are available for domestic use.24 They can help
improve the efficiency of health care and reduce their costs.25
In dentistry, POCs still play a tangential role, although
many authors underline the importance of, for example, a
chairside aMMP-8 test for monitoring disease progression
and adapting preventive and therapeutic measures.26–29 The
aMMP-8 test is inexpensive, easy to use (the results are auto-
mated and, therefore, independent of the practitioner’s expe-
rience), and currently available for routine use by dental and
medical professionals linking these disciplines.27 The authors
point out, that additional work, especially on the prognostic
value of biomarkers in periodontal and peri-implant diseases,
is still required.
Recently it was proposed that the combination of biomark-
ers (such as MMP-8) with bacterial determination (such as P.
gingivalis) could result in a promising diagnostic or monitor-
ing tool for periodontitis.26,28
A further, newly developed “chairside test” (CST) enables
the detection of five periodontal pathogens in a time span
of ≈20 minutes, but to date no data on CST’s sensitivity
and specificity is available. Therefore, the aim of this clinical
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study was to determine the detection level of CST, its sensitiv-
ity and specificity for the detection of the five most relevant
periodontal pathogens and compare the results with qPCR as
reference. Secondary aims were the investigator reliability as
well as the relationship to the clinical situation.
2 MATERIALS AND METHODS
2.1 Study center and subjects
A sample-size calculation by ACOMED Statistik∗ revealed
that 100 periodontally diseased and 25 periodontally healthy
individuals needed to be included in this study. The neces-
sary sample size was evaluated using simulations of probit
analysis for estimation of limit of detection (LoD) when the
samples are measured in duplicates. Awidth of the 95% confi-
dence interval (CI) of about 0.5 units can be established, when
a sample size of 50 is used. Taking into account low preva-
lences of some of the targets, a larger sample size of 100 was
chosen. Twenty-five healthy subjects are efficient to estimate
an assumed 100% specificity with a 12% width of the lower
one-sided Pearson-Clopper 95% CI.
Subjects were selected from the pool of patients at the
Department of Periodontology (diseased group) while healthy
subjects included staff and students of the Marburg Dental
Clinic, Germany.
2.2 Study population and inclusion criteria
All participants were divided into a periodontally diseased
and a healthy group by means of the following inclusion crite-
ria: 1) age≥18 years, 2) no intake of antibiotics within the pre-
vious 6 months, and 3) no treatment with antibacterial mouth-
washes in the last 6 months.
“Periodontally diseased” study participants (with
moderate-to-severe periodontitis according to the 1999
International Classification30) had at least two pockets with
probing depths ≥5 mm and positive BOP.
“Periodontally healthy” study participants (control group)
had probing depth of 1 to 3 mm and no negative BOP.
Upon written informed consent a total of 125 partici-
pants (59 females, 66 males) at an average age of 52.2 ±
16.9 years were included. One hundred patients (44 females
and 56males; 57.4± 13.7 years) were classified as “periodon-
tally diseased.” The control group consisted of 25 “periodon-
tally healthy” participants (15 females, 10males) at an average
age of 31.3 ± 11.23 years.
2.3 Study design and procedure
This single-center, prospective, case-controlled study (Fig. 1)
followed the current guidelines of the United States’ Food and
∗ACOMED Statistik, Leipzig, Germany.
Drug Administration (FDA 2007)31 and the Clinical and Lab-
oratory Standards Institute (CLSI 2008).32 The investigation
of the CST was registered with the corresponding authorities
(DIMDI: DE/CA99/5901) and ethic commission as a medi-
cal product law (MPG/in vitro diagnostic study). The Medical
Ethics Committee at Philips-University Marburg, Germany
approved this study (#84/10). All anonymized study partic-
ipants received a three-digit identification number according
to the order of recruitment and independent of “healthy” or
“diseased” criteria.
2.4 Sample collection and implementation of
the chairside test
Sample collection as well as reading the CST chip was per-
formed by the investigators (NA and TA) independently of one
another to assess examiners reliability. For each patient, two
sampling areas were specified and supragingivally debrided.
Using tweezers, a sterile paper point (ISO 35)† was then
placed into the base of the pocket for ≈20 seconds to absorb
sulcular fluid (subgingival plaque sample). In healthy partici-
pants paper points were inserted 1 to 2 mm into the sulcus, as
no periodontal pockets were present. Afterwards, paper points
of each patient were pooled and placed into one reaction tube,
pre-filledwith glass beads. For anonymization, each tube got a
sticker with the study participants’ identification number and
the date the samples were taken. The identification number
drew no association to the origin of the sample.
Paper points were immersed in 160 µL of lysis solution,
which was added into the reaction tube. The tube was imme-
diately shaken for 30 seconds to extract the bacterial nucleic
acids. Samples were then heat-treated for 6 minutes in boiling
water. Immediately following this step, 20 µL of this hot sam-
ple solutionwere pipetted into the inlet of each of the test chips
and drawn into the sample channel by capillary forces. After
2 minutes of incubation, the following solutions were addi-
tionally added into the inlet in the listed order while waiting
2 minutes before adding the next solution: 1) Enzyme solution
in preparation of the color reaction; 2) Washing solution to
remove unspecifically boundmolecules; and 3) Color reaction
solution for visualization of hybridization through an enzyme
reaction. After waiting an additional 4 minutes, results on test
chips were interpreted. A weak or strong blue coloration rep-
resented a positive reaction (i.e., bacteria present) (Fig. 2).
The legend of the abbreviated bacteria names (e.g., T. den-
ticola = T.d.) were imprinted next to the channel on the chip
and provided easy identification of the corresponding signal.
Additionally, three controls on the chip became visible after
a successful test procedure: the C1 signal confirms a success-
ful hybridization (i.e., binding to the probe), the C2 signal the
functioning of the enzyme, and the signal related to the total
†DiaDent Group International, Burnaby, British Columbia.
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F IGURE 1 Summary of the study design
F IGURE 2 Picture of a test slide of CST
germ load confirms correct sampling and efficient bacterial
lysis.
Each sample was tested twice using two CST test chips by
two examiners (NA, TA) independently of one another.
2.5 Quantitative real-time PCR as a method
for comparison
The leftover sample lysate (≈120 µL each) was sealed tightly
with Parafilm M,∗ immediately frozen, and stored at −20◦C.
Samples were shipped on dry ice to the laboratory† and ana-
lyzed using quantitative real-time PCR (qPCR) as reference.
DNA was extracted using the GenElute Bacterial Genomic
DNA Kit‡ according to manufacturer’s protocol and a spe-
cific PCR was performed using SYBR Green Supermix.§ The
PCR reactionmixture was prepared in a total volume of 25 µL,
using 12.5 µL ready-to-use reaction cocktail, 10.5 µL PCR-
grade H2O, 0.5 µL forward primer (2 µM), 0.5-µL reverse
primer (2 µM), and 1-µL template. The reactions were set up
∗Bemis, Neenah, WI.
† Lambda, Rainbach, Austria.
‡ Sigma-Aldrich, St. Louis, MO.
§ Sigma-Aldrich, St. Louis, MO.
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in 96-well optical plates∗ and amplified using a C1000 Ther-
mal Cycler with a CFX96 Real-Time System.† Cycling con-
ditions were 10 minutes at 94◦C; 40 cycles of 30 seconds at
94◦C, 40 seconds at 60◦C or 63◦C or 67◦C for T.d., T. f.,
P.g., P.i., and A.a., respectively, 40 seconds at 72◦C, and a
final extension at 72◦C for 3 minutes. Proprietary primers
targeting the 16S rRNA-region to perform species-specific
amplification were used. Standardized positive and negative
controls were included in the runs. All samples were tested in
double.
2.6 Artificial enrichment of Aggregatibacter
actinomycetemcomitans
The prevalence of the bacterium A. actinomycetemcomitans
(even in periodontally diseased patients) is very low. How-
ever, since its incidence is important for the comparison of
the detection ability, 16 of 100 samples of the diseased group
were artificially enriched with A. actinomycetemcomitans.
This occurred through the addition of spiked lysis solution,
which was masked for the examiner. Eight different concen-
trations were used to cover a range of bacterial loads. For
16 of the randomly selected patient samples 160 µL of each
“enriched” lysis solution was added (rather than the origi-
nal). The CST was completed twice. Therefore, every dilution
was used two times. This ensured a protocol for the enriched
bacterial marker not deviating from that of the clinical
test.
2.7 Data management/data collection forms
Data regarding patient’s clinical diagnosis (healthy/diseased)
were documented anonymously on data collection sheets.
CST results of both examiners were recorded independently.
These data as well as the results of the comparison method
were transferred into three Microsoft Excel‡ tables and sent
anonymously to ACOMED Statistik§ who completed statisti-
cal data analysis.
2.8 Statistical analysis
The primary aim of the study was the determination of the
detection limit of CST for the five periodontal pathogens
each as well as sensitivity and specificity for the detection
compared with qPCR as reference. Secondary aims were
examiner’s reliability and relationship to the clinical situation
(periodontally healthy or diseased).
∗Quanta Bioscience, Gaithersburg, MD.
†Bio-Rad, Hemel Hepstead, UK.
‡Microsoft Excel, Redmond, WA.
§ ACOMED Statistik, Leipzig, Germany.
TABLE 1 Cross tabulation for overall sensitivity and specificity
of CST for each investigator and investigators’ reliability
(Investigator 1, Investigator 2)
Bacterial detection by CST
Clinical finding Positive Negative Total (valid)
Investigator 1
Diseased 169 29 198
Healthy 0 50 50
Sensitivity 169/198 85.35%
Specificity 50/50 100%
Investigator 2
Diseased 169 30 199
Healthy 0 50 50
Sensitivity 169/199 84.92%
Specificity 50/50 100%
Investigator reliability 99.2%
3 RESULTS
3.1 Investigator reliability
Investigator’s reliability was tested using 500 results for the
determination of the two test chips for each of the 125 partic-
ipants (investigated independently by two examiners). Inves-
tigator 1 could not read two test chips, Investigator 2 could
not read one test chip; thus for investigator 1, 198 results from
“diseased group” (and 50 “healthy results”), and for Investiga-
tor 2, 199 in diseased group (and 50 “healthy results”) could
be used for evaluation. Both examiners showed identical eval-
uation in 248 of 250 test chips, the investigator reliability was
99.2% (Table 1).
3.2 Sensitivity and specificity in relation to
the clinical situation
Both CST and qPCR showed a specificity of 100%, which
means that no test system found the five pathogens in healthy
subjects (Table 2). The sensitivity of CST was 85.14% com-
pared with 94% for reference method qPCR, meaning that
both methods did not detect bacteria in all samples of diseased
patients.
3.3 Limit of detection, sensitivity with respect
to qPCR, “corrected” sensitivity and bacterial
prevalence
The LoD was defined as the concentration from the quanti-
tative determination (qPCR) at which 50% of the CST results
are positive. The determination was carried out by probit anal-
ysis. LoD was specified together with the corresponding 95%
CI. The calculated LoD of the CST for individual bacteria and
the percentage of positive detection by qPCR are presented in
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TABLE 2 Cross tabulation for bacterial detection in relation to the clinical findings (groups) (CST: n = 397; qPCR: n = 100)
CST qPCR
Bacterial
detection Diseased Healthy Diseased Healthy
Positive 338 0 94 0
Negative 59 100 6 25
Sensitivity 85.14% (338/397) 94% (94/100)
Specificity 100% /100/100) 100% (25/25)
TABLE 3 Prevalence of the bacteria in diseased group with CST
and qPCR, sensitivity of CST, and calculated limit of detection
Bacterial
species
Pos.
detection
CST in %
Pos.
detection
qPCR in
%
Sensitivity
CST/
qPCR in
%a
Calculated
detection
limit of
CST
T. denticola 73 85 85.89 1.2 × 104
T. forsythia 69 94 73.41 1.2 × 104
P. gingivalis 57 74 77.03 2.5 × 104
P. intermedia 24 52 46.16 5.3 × 104
A. actinomycete
mcomitans
15b 31b 48.39 5.8 × 104
aSensitivity in relation to the maximum positive detection of the CST based on the
calculated detection limit.
bArtificially enriched.
TABLE 4 Corrected sensitivity based on maximum possible
detection of CST
Bacterial species
Maximum
potential for
CST in %a
Corrected
sensitivitya
T. denticola 80 91.3
T. forsythia 80 86.3
P. gingivalis 68 83.8
P. intermedia 28 85.7
A. actinomycetemcomitans 15 100
aBased on the calculated detection limit of CST.
Table 3. Thus, the following prevalence was found for CST: T.
denticola in 73%, T. forsythia in 69%, P. gingivalis in 57%, P.
intermedia in 24%, and A. actinomycetemcomitans in 15% of
the samples. Using qPCR, T. denticola was found in 85%, T.
forsythia in 94%, P. gingivalis in 74%, P. intermedia in 52%,
and A. actinomycetemcomitans in 31% of the samples.
Based on LoD, the maximum number of possible detection
of the CST was assessed and resulted in the maximum poten-
tial for CST, and thus, in a “corrected” sensitivity compared
with qPCR of 91.3% for T. denticola, 86.3% for T. forsythia,
83.3% for P. gingivalis, 85.7% for P. intermedia, and 100% for
A. actinomycetemcomitans (Table 4).
4 DISCUSSION
The aim of the present study was to determine the detection
level of a new and innovative CST, its sensitivity and speci-
ficity for the detection of the five most relevant periodontal
pathogens and compare the results with qPCR as a bench-
mark reference. Furthermore, precision and accuracy of the
test between different users as well as on predicting clinical
findings (i.e., periodontally diseased or healthy) were exam-
ined. Comparison with qPCR (instead of end-point PCR) was
necessary to actually quantify the bacterial load and determine
the LoD. The results of other methods such as checkerboard
DNA-DNA hybridization or DNA strip technology are at best
semi-quantitative and could, therefore, not be used for quan-
titation.
Mainly A. actinomycetemcomitans, P. gingivalis, T.
forsythia, T. denticola, and P. intermedia significantly influ-
ence disease initiation and progression, as they are associated
in complexes of more or less pathogenicity.2,33 Bacterial
determination by microbiological testing is important to
monitor the disease and was proposed as part of routine
diagnostics in severe cases.7
In the present study, prevalence of 73%/85% (CST/qPCR)
for T. denticola, 69%/94% for T. forsythia, 57%/74% for P.
gingivalis, 24%/52% for P. intermedia, and 15%/31% for A.
actinomycetemcomitans, respectively, was shown (Table 3).
These are in line with other studies using similar inclusion
criteria. While Jervoe-Storm et al.22 found 44% for P. gin-
givalis, 44% (P. intermedia), and 8% (A. actinomycetem-
comitans) with real-time PCR (at a detection level of 102),
Cosgarea et al.34 identified with PADO∗ test (detection
threshold of 103 for A. actinomycetemcomitans and 104 for
all other bacteria)/MERI† test (detection threshold of 102)
a prevalence of 91%/93% for T. denticola, 91%/96% for T.
forsythia, 73%/78% for P. gingivalis, and 19%/25% for A. acti-
nomycetemcomitans. Similar results, using different qPCR
methods are provided by Polonyi et al.35 They detected T. den-
ticola in 76%, T. forsythia in 98%, P. gingivalis in 80%, P.
intermedia in 33%, and A. actinomycetemcomitans in 10% of
∗ IAI Pado Test 4.5®, Zuchwil, Switzerland
†Meridol® Paro Diagnostik, Gaba GmbH, Lörrach, Germany
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all investigated samples. It should be kept in mind that in this
present study the amount of A. actinomycetemcomitans was
artificially enriched by immersing the paper points in defined
dilutions. This was necessary to receive enough data to assess
and evaluate the potential of CST considering its expected low
prevalence.
A specificity of 100% for both CST and qPCR showed
that both test systems did not detect the five pathogens in the
periodontally healthy study population of the present study,
which differs to the findings of Jervoe-Storm et al.22 in a sim-
ilar study presenting a specificity of only 84% for the qPCR,
meaning that in some cases also healthy subjects carried the
pathogens.
A sensitivity between 46% (for P. intermedia) and 86% (for
T. denticola) of the CST compared with the reference method
demonstrates that the presence of bacteria could not be ver-
ified in all samples that were detected by qPCR. This opens
the discussion for the difficulty in finding a proper reference
method. Since the qPCRmethod provides a quantitative result
while the CST provides a dichotomous decision (i.e., bac-
teria present or bacteria not present) a comparison between
both methods is of limited extent. The qPCR is accepted as
the gold standard and is able to detect extremely small num-
bers of bacteria (about 500 to 900 bacteria) since it amplifies
the results. As there is no other reference method, it has to
be considered that qPCR detects also dead bacteria’s DNA.
The method of the CST is based on RNA detection. It prin-
cipally detects living bacteria that can proliferate and could
cause damage in the periodontal pocket althoughRNA ismore
unstable than DNA.30 In this context, Polonyi et al.35 point
out that DNA is slowly degraded after vitality loss. Under cer-
tain circumstances it might even be detectable years after cell
death. Thus, they recommend the use of RNA-based detection
methods especially to verify successful eradication of peri-
odontal pathogens.
Hence, it is natural that qPCR is more sensitive, which is
reflected in the detection limit of 102 in the present study,
which is comparable with other studies that used qPCR to
detect periodontal pathogens.22,34,36 The detection limit of the
CSTwas 104, and therefore, higher than the qPCR. A different
rRNA-based test (iai Pado)∗ detected A. actinomycetemcomi-
tans out of 103 bacteria and other periodontal pathogens out
of 104.34,36 In conclusion, the detection limits of the CST are
in range to the ones in the PADO test. However, when regard-
ing detection limits it should be kept in mind that also healthy
individuals can be colonized by periodontal pathogens and the
amount of periodontal pathogens plays a role in developing
periodontal disease.
To overcome difficulties when comparing different test
systems, a corrected sensitivity was calculated by setting the
∗ iai Pado, Zuchwil, Schweiz.
results in relationship to the maximum potential of the CST.
The corrected sensitivity (i.e., the sensitivity within the detec-
tion limit of≈1.2 to 5.8 × 104) can be classified as “excellent”
with values between 84% and 100% according to a similar
study for A. actinomycetemcomitans detection where sensi-
tivity of 67% and the specificity of 100% were classified as
“excellent.”22
Having high investigator reliability is important for a new
test to guarantee that the application is easy to handle. A
consensus of 99.2% can be classified as “excellent,” a min-
imal difference could also be explained by a little time-span
between read-outs in band intensities.
The newly developed CST is able to detect five typical peri-
odontal pathogens; however, with a higher detection limit than
qPCR. For the clinical practice routine, it is discussable if the
periodontal therapy needs exact numbers of the bacteria or if
the presence or absence of pathogenetic bacteria or better said
their virulent RNA is sufficient. A somewhat lower sensitiv-
ity than the reference method can still be classified as “good,”
especially due to the fact that RNA-based methods justifi-
ably detect living bacteria as opposed to DNA-based reference
methods.
5 CONCLUSIONS
CST offers the opportunity to get a quick overview over
virulent periodontal pathogens in patients’ pockets at the
POC with immediate results and could, therefore, provide an
advantage over traditional microbiological assessment pro-
cedures (e.g., qPCR). CST can at least be a helpful tool in
periodontal diagnostics to support the decision to supplement
periodontal therapy with or without antibiotics and there-
with help to choose the most appropriate and personalized
approach to treatment.
Drawbacks of the method are 1) that the results are qualita-
tive (yes or no) and provide only the information that bacteria
are present above the calculated LoD and 2) that the visual
interpretation of the results might be difficult in some cases
although two independent investigators had a high agreement
(98.7%). Therefore, a method to objectively identify positive
signals, for example, using a software application with an
electronic reporting systemwould be helpful which also could
document and store the results.
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